Clinical Advisory Board
Dr Tiziana Di Martino
Medical doctor with a career rooted in clinical practice and microbial diagnostics. Previously led Clinical Development (EMEA) at Accelerate Diagnostics and later served as Chief Medical Officer at Q-linea, where she provided strategic and clinical leadership across health economics, clinical outcomes research, and the real-world adoption of rapid AST for bloodstream infection and sepsis care pathways.
Stephen Kidd
A microbiology and diagnostics specialist with deep expertise in antimicrobial susceptibility testing (AST) and antimicrobial resistance (AMR). Based in Basingstoke, he advises on translating AST innovation into routine practice—bridging method development, quality systems, and clinical adoption. His guidance spans EUCAST/CLSI-aligned methods, verification/validation under ISO 15189 and ISO 13485 frameworks, and integration of rapid and automated AST into high-throughput workflows and LIMS. Regularly supports product strategy for IVD teams—shaping clinical studies, usability and workflow design, health-economic value cases, and market access across the UK and EU.
Scott O'Brien
Diagnostics commercialization leader focused on AST/AMR implementation in U.S. healthcare systems. He bridges product development and real-world adoption—aligning CLSI-concordant methods, CLIA/CAP-ready verification plans, and workflow design for rapid and automated AST with LIS integration. Previously served as Senior Vice President of Global Marketing/International Sales at GenMark Diagnostics and as Chief Commercial Officer at Specific Diagnostics.
Dr. Stefan Riedel
Dr. Stefan Riedel is the Associate Medical Director of the Clinical Microbiology Laboratories at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and holds an academic appointment as Associate Professor of Pathology at Harvard Medical School.
Dr. Riedel’s research is focused on the diagnosis and management of sepsis as well as emerging antimicrobial resistance in gram-negative bacteria. His research laboratory is focused on clinical trials in laboratory medicine, with expertise in regulatory aspects for novel in-vitro diagnostic test methods for the U.S. and international markets. His research is focused on the diagnosis of sepsis and the surveillance and detection of antimicrobial resistance, specifically in Gram-negative bacteria. Studies include blood culture diagnostics, MALDI-ToF MS, phenotypic, genotypic, and rapid antimicrobial susceptibility testing, in conjunction with antimicrobial stewardship and clinical outcomes evaluations. He has authored numerous papers and book chapters on topics in microbiology, sepsis, antimicrobial resistance and antimicrobial susceptibility testing, as well as general laboratory diagnostic testing methods. In addition, he is a member of the editorial board of the Journal of Clinical Microbiology, and is the editor-in-chief of a Medical Microbiology textbook, used in many national and international medical schools.
Dr. Riedel currently serves as an advisor to the National Antimicrobial Susceptibility Testing Committee for the United States (USCAST). In the past, Dr. Riedel served as the President of the North East Branch of the ASM, and he was a member of the College of American Pathologists (CAP) Microbiology Resource Committee.
Dr. Riedel received his M.D. and Ph.D. degrees from the Johann Wolfgang Goethe University in Frankfurt, Germany. After initial clinical training in general and orthopaedic surgery in England, Germany, and Switzerland, he completed residency training in anatomic and clinical pathology at Baylor University Medical Center in Dallas, TX, followed by a 2-year fellowship in medical and public health microbiology at the University of Iowa Hospitals & Clinics in Iowa City, IA. Dr. Riedel is board certified in Clinical Pathology and Medical Microbiology by the American Board of Pathology, and is a diplomate of the American Board of Medical Microbiology (ABMM).